Anti-estrogenic treatment and HER2 inhibitors are used to treat hidradenocarcinoma, mucinous carcinoma, or apocrine adenocarcinoma, with variable outcomes [90,98,156]. The gene discussed is ERBB2; the disease is apocrine adenocarcinoma.